Embla Medical

	21/10 08:39 af ProInvestorNEWS	Medwatch: (link)
	21/10 06:56 af ProInvestorNEWS	Børsen: Embla Medicals ser vækstmulighed i forbedret tilskudssituation i USA. Flere får adgang til avancerede proteser, og det kan sikre Embla Medicals vækst næste år. (Side 10)
	17/10 16:02 af ProInvestorNEWS	OBS: Embla Medical har en betalt digital IR-aftale med ProInvestor.com
	17/10 16:01 af ProInvestorNEWS	Webcast på dansk fra Økonomisk Ugebrev (link)
	17/10 16:00 af ProInvestorNEWS	Kilde: Klaus Sindahl Head of Investor Relations Embla-Medical
	17/10 15:59 af ProInvestorNEWS	The business recorded USD 23m in sales in 2023 (mainly Germany) and Embla will utilize its commercial footprint to expand the business globally. F&G is accretive.
	17/10 15:58 af ProInvestorNEWS	Neuro Orthotics Back in January this year Embla acquired a German Neuro Orthotic Business Fior & Gentz for EUR 100m. F&G develops and manufacture "technical orthotics" (bionic joints) for patients suffering from disabled mobility following e.g. stroke, MS, CP. Neuro Orthotics is perhaps 10-20 years after prosthetics in terms of awareness and reimbursement but with great growth potential.
	17/10 15:58 af ProInvestorNEWS	Innovation agenda 5% of revenue (USD ~30m) is invested in R&D annually with product launches every year. 70-80% of sales in prosthetics is reoccuring as the replacement cyle typically runs for 3-4 years. Two new bionic knee solutions (NAVII and ICON) were launched end of Q2 2024.
	17/10 15:58 af ProInvestorNEWS	Growth'27: Late March 2023, Embla Medical launched a new five-year growth ambition of 7-10% average growth (organic growth of 5-7% and M&A of 2-3%).
	17/10 15:57 af ProInvestorNEWS	Strong growth case with increasing Earnings and solid cash flow generation Since listing in 1999 the business has grown at ~17% CAGR driven by organic sales and acquisitions ~85% of EBIT converted into FCF in the past decade. For 2024 the Company is guiding 6-8% organic growth and ~20% EBITDA (22% in Q2 2024; up 3pp vs Q3 2023).
	17/10 15:57 af ProInvestorNEWS	Why is Embla an attractive case right now? US Medicare implemented extended coverage in September 2024 Coverage expansion will allow less mobile/low-active amputees (K2 patients) access to advanced bionic devices (previously restricted to K3/K4). The new reform is expected to contribute meaningfully to Embla's organic growth over the next 3-5 years
	17/10 15:55 af ProInvestorNEWS	Q2 2024 Report 2024 (July 23, 2024) (link)
	17/10 15:54 af ProInvestorNEWS	Q2 2024 Recent Embla Medical corporate deck (July 23, 2024) Roadshow presentation: (link)
	17/10 15:37 af ProInvestorNEWS	Velkommen til Embla Medical chat.